ENSYSCE BIOSCIENCES, INC. Financing Cash Flow
ENSYSCE BIOSCIENCES, INC. (ENSC) reported Financing Cash Flow of $1.83 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-13
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.89M, a 1.49% increase year-over-year.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was -$63.95K, a 105.08% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $4.16M, a 3597.95% increase year-over-year.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $1.45M, a 64.86% decline year-over-year.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2025 was $8.74M, a 11.57% decline from fiscal 2024.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2024 was $9.88M, a 12.85% increase from fiscal 2023.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2023 was $8.76M, a 0.11% decline from fiscal 2022.
- ENSYSCE BIOSCIENCES, INC. net cash provided by (used in) financing activities for fiscal 2022 was $8.77M, a 56.85% decline from fiscal 2021.
| Period end | Net Cash Provided by (Used in) Financing Activities 1 month | Net Cash Provided by (Used in) Financing Activities 3 month | Net Cash Provided by (Used in) Financing Activities 3 month as first filed | Net Cash Provided by (Used in) Financing Activities 4 month | Net Cash Provided by (Used in) Financing Activities 6 month | Net Cash Provided by (Used in) Financing Activities 6 month as first filed | Net Cash Provided by (Used in) Financing Activities 9 month | Net Cash Provided by (Used in) Financing Activities 9 month as first filed | Net Cash Provided by (Used in) Financing Activities 12 month | Net Cash Provided by (Used in) Financing Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $1.83M 10-Q · filed 2026-08-13 | $5.99M derived: sum of 3 quarters · filed 2026-08-13 | $7.44M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2026-03-31 | -$63.95K 10-Q · filed 2026-05-15 | $4.10M derived: sum of 2 quarters · filed 2026-05-15 | $5.55M derived: sum of 3 quarters · filed 2026-05-15 | $7.42M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-12-31 | $4.16M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $5.61M derived: sum of 2 quarters · filed 2026-03-30 | $7.48M derived: sum of 3 quarters · filed 2026-08-13 | $8.74M 10-K · filed 2026-03-30 | ||||||
| 2025-09-30 | $1.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $3.32M derived: sum of 2 quarters · filed 2026-08-13 | $4.58M 10-Q · filed 2025-11-14 | $4.69M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-06-30 | $1.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $3.12M 10-Q · filed 2026-08-13 | $3.24M derived: sum of 3 quarters · filed 2026-08-13 | $7.37M derived: sum of 4 quarters · filed 2026-08-13 | ||||||
| 2025-03-31 | $1.26M 10-Q · filed 2026-05-15 | $1.37M derived: sum of 2 quarters · filed 2026-05-15 | $5.50M derived: sum of 3 quarters · filed 2026-05-15 | $5.45M derived: sum of 4 quarters · filed 2026-05-15 | ||||||
| 2024-12-31 | $112.58K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | $4.24M derived: sum of 2 quarters · filed 2026-03-30 | $4.19M derived: sum of 3 quarters · filed 2026-03-30 | $9.88M 10-K · filed 2026-03-30 | ||||||
| 2024-09-30 | $4.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $4.08M derived: sum of 2 quarters · filed 2025-11-14 | $9.77M 10-Q · filed 2025-11-14 | $11.23M derived: sum of 4 quarters · filed 2025-11-14 | ||||||
| 2024-06-30 | -$51.23K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $5.64M 10-Q · filed 2025-08-13 | $7.10M derived: sum of 3 quarters · filed 2025-08-13 | $7.00M derived: sum of 4 quarters · filed 2025-08-13 | ||||||
| 2024-03-31 | $5.69M 10-Q · filed 2025-05-13 | $7.15M derived: sum of 2 quarters · filed 2025-05-13 | $7.05M derived: sum of 3 quarters · filed 2025-05-13 | $12.57M derived: sum of 4 quarters · filed 2025-05-13 | ||||||
| 2023-12-31 | $1.46M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-10 | $1.36M derived: sum of 2 quarters · filed 2025-03-10 | $6.88M derived: sum of 3 quarters · filed 2025-03-10 | $8.76M 10-K · filed 2025-03-10 | ||||||
| 2023-09-30 | -$102.45K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $5.42M derived: sum of 2 quarters · filed 2024-11-12 | $7.29M 10-Q · filed 2024-11-12 | $9.24M derived: sum of 4 quarters · filed 2024-11-12 | ||||||
| 2023-06-30 | $5.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-14 | $7.40M 10-Q · filed 2024-08-14 | $9.34M derived: sum of 3 quarters · filed 2024-08-14 | $16.82M derived: sum of 4 quarters · filed 2024-08-14 | ||||||
| 2023-03-31 | $1.87M 10-Q · filed 2024-05-13 | $3.82M derived: sum of 2 quarters · filed 2024-05-13 | $11.30M derived: sum of 3 quarters · filed 2024-05-13 | $11.03M derived: sum of 4 quarters · filed 2024-05-13 | ||||||
| 2022-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-15 | $9.42M derived: sum of 2 quarters · filed 2024-03-15 | $9.16M derived: sum of 3 quarters · filed 2024-03-15 | $8.77M 10-K · filed 2024-03-15 | ||||||
| 2022-09-30 | $7.48M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $7.22M derived: sum of 2 quarters · filed 2023-11-09 | $6.83M 10-Q · filed 2023-11-09 | $16.01M derived: sum of 4 quarters · filed 2023-11-09 | ||||||
| 2022-06-30 | -$265.81K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | -$657.08K 10-Q · filed 2023-08-11 | $8.53M derived: sum of 3 quarters · filed 2023-08-11 | $11.19M derived: sum of 4 quarters · filed 2023-08-11 | ||||||
| 2022-03-31 | -$391.27K 10-Q · filed 2023-05-15 | $8.80M derived: sum of 2 quarters · filed 2023-05-15 | $11.45M derived: sum of 3 quarters · filed 2023-05-15 | $19.31M derived: sum of 4 quarters · filed 2023-05-15 | ||||||
| 2021-12-31 | $9.19M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $11.85M derived: sum of 2 quarters · filed 2023-03-30 | $19.70M derived: sum of 3 quarters · filed 2023-03-30 | $20.31M 10-K · filed 2023-03-30 | ||||||
| 2021-09-30 | $2.66M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $10.51M derived: sum of 2 quarters · filed 2022-11-14 | $11.13M 10-Q · filed 2022-11-14 | $11.13M derived: sum of 4 quarters · filed 2022-11-14 | ||||||
| 2021-06-30 | $7.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $8.47M 10-Q · filed 2022-08-11 | $8.47M derived: sum of 3 quarters · filed 2022-08-11 | $8.77M derived: sum of 4 quarters · filed 2022-08-11 | ||||||
| 2021-03-31 | $612.86K 10-Q · filed 2022-05-12 | $297.50K 10-Q · filed 2021-06-08 | $612.86K derived: sum of 2 quarters · filed 2022-05-12 | $912.86K derived: sum of 3 quarters · filed 2022-05-12 | $137.00M derived: sum of 4 quarters · filed 2022-05-12 | |||||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | $300.00K derived: sum of 2 quarters · filed 2022-03-31 | $136.38M derived: sum of 3 quarters · filed 2022-03-31 | $1.10M 10-K · filed 2022-03-31 | -$183.55M 10-K · filed 2021-03-15 | |||||
| 2020-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-15 | $136.38M derived: sum of 2 quarters · filed 2021-11-15 | $1.10M 10-Q · filed 2021-11-15 | -$183.38M 10-Q · filed 2020-11-09 | -$9.92M derived: sum of 4 quarters · filed 2021-11-15 | |||||
| 2020-06-30 | $136.08M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16 | $800.02K 10-Q · filed 2021-08-16 | -$183.38M 10-Q · filed 2020-08-07 | -$10.22M derived: sum of 3 quarters · filed 2021-08-16 | -$10.22M derived: sum of 4 quarters · filed 2021-08-16 | |||||
| 2020-03-31 | -$135.28M 10-Q · filed 2021-06-08 | -$146.30M derived: sum of 2 quarters · filed 2021-06-08 | -$146.30M derived: sum of 3 quarters · filed 2021-06-08 | -$146.30M derived: sum of 4 quarters · filed 2021-06-08 | ||||||
| 2019-12-31 | -$11.02M derived: 10-K/A 12 month − 10-Q 9 month · filed 2021-06-08 | -$11.02M derived: sum of 2 quarters · filed 2021-06-08 | -$11.02M derived: sum of 3 quarters · filed 2021-06-08 | -$11.03M 10-K/A · filed 2021-06-08 | ||||||
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-09 | $0.00 derived: sum of 2 quarters · filed 2020-11-09 | -$8.64K 10-Q · filed 2020-11-09 | -$8.64K derived: sum of 4 quarters · filed 2020-11-09 | ||||||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | -$8.64K 10-Q · filed 2020-08-07 | -$8.64K derived: sum of 3 quarters · filed 2020-08-07 | -$8.64K derived: sum of 4 quarters · filed 2020-08-07 | ||||||
| 2019-03-31 | -$8.64K 10-Q · filed 2020-05-07 | -$8.64K derived: sum of 2 quarters · filed 2020-05-07 | -$8.64K derived: sum of 3 quarters · filed 2020-05-07 | -$8.64K derived: sum of 4 quarters · filed 2020-05-07 | ||||||
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-10 | $0.00 derived: sum of 2 quarters · filed 2020-03-10 | $0.00 derived: sum of 3 quarters · filed 2020-03-10 | -$32.00K 10-K · filed 2020-03-10 | ||||||
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $0.00 derived: sum of 2 quarters · filed 2019-11-07 | -$32.00K 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | -$32.00K 10-Q · filed 2019-08-07 | ||||||||
| 2018-03-31 | -$32.00K 10-Q · filed 2019-05-07 | |||||||||
| 2017-12-31 | $202.34M 10-K/A · filed 2019-03-12 | |||||||||
| 2017-09-30 | $345.00K 10-Q · filed 2018-01-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |